ATLANTA, Nov. 8, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming investor conferences.
Artivion's management team will present at the upcoming Stifel 2023 Healthcare Conference on Wednesday, November 15, 2023 at the Lotte New York Palace. The Company's presentation is scheduled to begin at 9:45a.m. ET. A live webcast can be accessed through Artivion's website, www.artivion.com, on the Investors page. An archived copy of the webcast will be available for 90 days on the same website.
Members of the management team will also host one-on-one meetings at the upcoming Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on Thursday, November 16, 2023. Due to the format of this event no webcast will be available.
About Artivion, Inc.
Headquartered in suburban Atlanta, Georgia, Artivion, Inc. is a medical device company focused on developing simple, elegant solutions that address cardiac and vascular surgeons' most difficult challenges in treating patients with aortic diseases. Artivion's four major groups of products include: aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues. Artivion markets and sells products in more than 100 countries worldwide. For additional information about Artivion, visit our website, www.artivion.com.
Contacts: | |
Artivion | Gilmartin Group LLC |
D. Ashley Lee | Brian Johnston / Lynn Lewis |
Executive Vice President & | Phone: 332-895-3222 |
Chief Financial Officer | This email address is being protected from spambots. You need JavaScript enabled to view it.';document.getElementById('cloak57e6a30015deeccb19f512f9d4e1f82c').innerHTML += ''+addy_text57e6a30015deeccb19f512f9d4e1f82c+'<\/a>'; |
Phone: 770-419-3355 |
| Last Trade: | US$26.73 |
| Daily Change: | 0.32 1.21 |
| Daily Volume: | 104,759 |
| Market Cap: | US$1.120B |
October 10, 2024 August 08, 2024 February 15, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
